Practical guidelines for multiplicity adjustment in clinical trials

Controlled Clinical Trials

Volumn 21, Issue 6, 2000, Pages 527-539

  Proschan, Michael A ^a,b   Waclawiw, Myron A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b II Rockledge Center   (United States)

Author keywords

Familywise error rate; Multiple comparisons

Indexed keywords

ADJUSTMENT; ARTICLE; CLINICAL RESEARCH; COMPARATIVE STUDY; MONITORING; PRACTICE GUIDELINE; PROBABILITY; STATISTICAL ANALYSIS;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; GUIDELINES; STATISTICS;

EID: 0034530370     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(00)00106-9     Document Type: Article

References (21)

1. No adjustments are needed for multiple comparisons
2. Multiple range and multiple F tests
3. The appropriateness of analysis of variance and multiple comparison procedures
4. Multiplicity in clinical trials
5. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
6. Testing the hypothesis that matters for multiple primary endpoints
7. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
8. Multiple comparisons with control in a single experiment versus separate experiments: Why do we feel differently?
9. P-value interpretation and Alpha allocation in clinical trials
10. Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation
11. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
12. A randomized study of the prevention of sudden death in patients with coronary artery disease
13. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
14. Planning and analysis of repeated measures at key time-points in clinical trials sponsored by pharmaceutical companies
15. Simultaneous Inference
16. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
17. A multiple comparison procedure for three- and four-armed controlled clinical trials
18. Alpha calculus in clinical trials: Considerations and commentary for the new millennium